HBOT accepted uses: UHMS indications and FDA clearance

What does approved HBOT actually mean?

HBOT has accepted medical uses, including decompression sickness, carbon monoxide poisoning, and selected difficult wounds. Whether it is appropriate for you depends on the exact diagnosis and your circumstances. An advertisement saying “approved” does not answer that question.

FDA clearance concerns a particular medical device and its intended use. The Undersea and Hyperbaric Medical Society, or UHMS, maintains a professional list of accepted indications. Medicare applies a national coverage policy. These decisions answer different questions; none can establish your personal eligibility by itself.

Use the list below as a starting point for a consultation. Ask the clinician to name the condition they are treating and explain how your situation fits the relevant indication. Keep a copy of that explanation alongside the proposed plan so another clinician can assess the same proposal.

UHMS accepted indications

The UHMS indications page lists these 15 groups as of October 2, 2026. Some include subgroups. Each has patient-selection requirements; a condition appearing here does not mean every person with it should receive HBOT.

• Air or gas embolism.
• Carbon monoxide poisoning, including carbon monoxide poisoning complicated by cyanide poisoning.
• Clostridial myositis and myonecrosis, also called gas gangrene.
• Crush injury, compartment syndrome, and other acute traumatic ischemias.
• Decompression sickness.
• Arterial insufficiencies: central retinal artery occlusion and enhancement of healing in selected problem wounds.
• Severe anemia.
• Intracranial abscess.
• Necrotizing soft tissue infections.
• Refractory osteomyelitis.
• Delayed radiation injury involving soft tissue or bony necrosis.
• Compromised grafts and flaps.
• Acute thermal burn injury.
• Idiopathic sudden sensorineural hearing loss.
• Avascular necrosis, also called aseptic osteonecrosis.

Poisoning, decompression illness, and gas bubbles

Some accepted uses belong in emergency care. Carbon monoxide poisoning can disrupt oxygen delivery and injure the heart and nervous system; clinicians consider HBOT according to the severity and circumstances. It is a poisoning treatment question, rather than a general way to remove unspecified toxins. Suspected exposure needs urgent medical assessment.

In decompression sickness, pressure changes can produce inert-gas bubbles and tissue injury. Recompression with oxygen helps reduce bubbles, eliminate inert gas, and support oxygen delivery. Air or gas embolism concerns bubbles within blood vessels and also needs specialist emergency assessment. An emergency team should arrange appropriate care; a nearby routine chamber listing does not establish readiness for these conditions.

Severe infection and threatened tissue

Gas gangrene, necrotizing soft tissue infection, selected intracranial abscesses, and refractory osteomyelitis concern serious infections. HBOT can be considered within a broader medical and surgical plan. Refractory osteomyelitis means bone infection that persists or returns despite appropriate treatment; the indication does not cover every bone infection or replace antibiotics and needed surgery.

Crush injuries, compartment syndrome, and other acute traumatic ischemias involve threatened tissue with impaired blood flow. HBOT may support tissue oxygenation alongside urgent standard treatment; it does not correct every cause of impaired circulation. Acute burns and severe anemia are also narrowly defined clinical applications, rather than evidence for routine skin care or ordinary fatigue.

Selected wounds, radiation injury, and grafts

For selected difficult wounds, the goal is to support healing in tissue that is not getting adequate oxygen. Selection and continuing wound care matter. Diabetes alone, or simply having an open wound, does not establish suitability. The assessment should address the wound and the reasons healing is impaired.

Delayed radiation injury concerns damaged tissue after radiotherapy, including soft tissue and bone necrosis. Treating this complication is different from claiming HBOT treats cancer itself. Compromised grafts and flaps are transferred tissues threatened with failure; the accepted use supports tissue rescue, rather than routine treatment of every healthy graft. HBOT is often part of care coordinated with other medical or surgical specialists.

Hearing, retinal circulation, and avascular necrosis

Idiopathic sudden sensorineural hearing loss concerns a sudden inner-ear hearing loss without an identified cause, rather than ordinary age-related hearing loss. Central retinal artery occlusion involves blocked blood flow to the retina. These are time-sensitive conditions needing immediate medical assessment; an HBOT discussion should be coordinated with the relevant specialists. AHA identifies retinal artery occlusion as an acute ischemic stroke and medical emergency.

Avascular necrosis, or aseptic osteonecrosis, concerns bone damage associated with inadequate blood supply. UHMS includes it as its fifteenth accepted indication. Ask how the location and stage of bone disease affect a recommendation and its relationship to orthopedic care. Acceptance does not imply that HBOT reverses all stages of bone collapse or replaces every surgical option.

FDA device clearance and labeling

FDA identifies hyperbaric chambers under product code CBF as Class II devices reviewed through the 510(k) pathway. This pathway assesses substantial equivalence to a legally marketed device. Ask for the manufacturer, exact chamber model, clearance number, and indications for use supporting the proposed purpose.

Registration or device listing does not establish FDA approval, clearance, or authorization. A registration certificate, an FDA logo in advertising, or a generic statement that oxygen therapy is approved does not resolve the status of the chamber or the use being offered. Bring the model and clearance details to the prescribing clinician if the explanation is unclear.

The most helpful question is whether this device’s cleared labeling includes the proposed use. Avoid treating a fixed internet count of FDA-approved conditions as the answer for every model. If the proposed purpose falls outside the labeling, request a specific discussion of evidence, alternatives, uncertainties, and consent before making a decision.

Claims outside accepted indications

FDA’s accessible July 2021 consumer bulletin warns about centers promoting HBOT for cancer, Lyme disease, autism, and Alzheimer’s disease without FDA clearance or approval for those uses. For an advertised use outside accepted indications, ask the clinician to explain the current evidence and regulatory status. Testimonials alone cannot establish whether the treatment helps.

Request the studies that support the exact claim, the population studied, and the outcome measured. Ask whether the service is being offered as established care, an emerging application, or participation in research. A discussion of possible mechanisms should be followed by evidence about outcomes that matter to people with your condition.

Coverage and urgent assessment

Medicare’s national policy differs from the UHMS indication list. A professionally accepted indication may still fall outside national Medicare coverage, and a covered category can have additional conditions. Confirm the diagnosis and documentation requirements with the treating team and insurer before interpreting a recommendation as a coverage promise.

Some conditions need prompt assessment before any routine clinic comparison. NIDCD describes sudden deafness symptoms as a medical emergency and advises seeing a doctor immediately. Do not postpone that assessment while looking for an HBOT appointment or waiting for a directory response.

Questions to ask

• What exact diagnosis and disease stage support your recommendation?
• Which UHMS indication and which device labeling apply?
• What evidence applies to people with my condition?
• What will count as benefit, and when will the plan be reviewed?

Sources